TY - JOUR
T1 - Contemporary use of devices in chronic heart failure in the Netherlands
AU - Raafs, A.G.
AU - Linssen, G.C.M.
AU - Brugts, J.J.
AU - Erol-Yilmaz, A.
AU - Plomp, J.
AU - Smits, J.P.P.
AU - Nagelsmit, M.J.
AU - Oortman, R.M.
AU - Hoes, A.W.
AU - Brunner-La Rocca, H.P.
N1 - Funding Information:
This work was supported by Servier, the Netherlands, funded the inclusion of data and software programme. The steering committee (JB, GL, AH, and HBRLR) received no funding for this project. This combined analysis was initiated by the authors and was designed, conducted, interpreted, and reported independently of the sponsor. The current study had no other funding source or any with a participating role in outcome assessment or writing of the manuscript. All authors had joint responsibility for the decision to submit for publication.
Funding Information:
This work was supported by Servier, the Netherlands, funded the inclusion of data and software programme. The steering committee (JB, GL, AH, and HBRLR) received no funding for this project. This combined analysis was initiated by the authors and was designed, conducted, interpreted, and reported independently of the sponsor. The current study had no other funding source or any with a participating role in outcome assessment or writing of the manuscript. All authors had joint responsibility for the decision to submit for publication. The authors thank the HF nurses and cardiologists of all participating centres for their participation in including patients and recording patient data.
Publisher Copyright:
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Aims Despite previous surveys regarding device implantation rates in heart failure (HF), insight into the real-world management with devices is scarce. Therefore, we investigated device implantation rates in HF with reduced left ventricular ejection fraction (LVEF) in 34 Dutch centres.Methods and results A cross-sectional outpatient registry was conducted in 6666 patients with LVEF < 50% and with information about device implantation available [74 (66-81) years of age; 64% male]. Patients were classified into conventional pacemakers (PM, n = 562), implantable cardioverter defibrillators (ICD, n = 1165), and cardiac resynchronization therapy with defibrillator function (CRT-D, n = 885) or pacemaker function only (CRT-P, n = 248), or no device (n = 3806). Centres were divided into ICD-implanting and CRT-implanting and referral centres. Overall, 17.5% had an ICD, 13.3% CRT-D, 3.7% CRT-P, and 8.4% PM. Of those with LVEF <= 30%, 42.5% had ICD or CRT-D therapy. A large variation in implantation rates existed between centres: 3-51% for ICD therapy, 0.3-44% for CRT-D therapy, 0-11% for CRT-P therapy, and 0-25% PM therapy. Implantation centres showed higher implantation rates of ICD, CRT-D, and CRT-P compared with referral centres [36% vs. 25% for defibrillators (ICD or CRT-D) and 17% vs. 9% for CRT devices (CRT-D or CRT-P), respectively, P < 0.001], independently of other factors. A large number of clinical factors were predictive for device usage. Among other, LVEF < 40% and male sex were independent positive predictors for ICD/CRT-D use [odds ratio (OR) = 3.33, P < 0.001; OR = 1.87, P = 0.019, respectively]. Older age was independently associated with less ICD/CRT-D (OR = 0.96 per year, P < 0.001) and more CRT-P/PM use (OR = 1.03 per year, P = 0.006).Conclusions In this large Dutch HF registry, less than half of the patients with reduced LVEF received an ICD or CRT, even if LVEF was <= 30%, and a large variation between centres existed. Patients from implantation centres had more often ICD or CRT. More uniformity regarding guideline-based use of device therapy in clinical practice is needed.
AB - Aims Despite previous surveys regarding device implantation rates in heart failure (HF), insight into the real-world management with devices is scarce. Therefore, we investigated device implantation rates in HF with reduced left ventricular ejection fraction (LVEF) in 34 Dutch centres.Methods and results A cross-sectional outpatient registry was conducted in 6666 patients with LVEF < 50% and with information about device implantation available [74 (66-81) years of age; 64% male]. Patients were classified into conventional pacemakers (PM, n = 562), implantable cardioverter defibrillators (ICD, n = 1165), and cardiac resynchronization therapy with defibrillator function (CRT-D, n = 885) or pacemaker function only (CRT-P, n = 248), or no device (n = 3806). Centres were divided into ICD-implanting and CRT-implanting and referral centres. Overall, 17.5% had an ICD, 13.3% CRT-D, 3.7% CRT-P, and 8.4% PM. Of those with LVEF <= 30%, 42.5% had ICD or CRT-D therapy. A large variation in implantation rates existed between centres: 3-51% for ICD therapy, 0.3-44% for CRT-D therapy, 0-11% for CRT-P therapy, and 0-25% PM therapy. Implantation centres showed higher implantation rates of ICD, CRT-D, and CRT-P compared with referral centres [36% vs. 25% for defibrillators (ICD or CRT-D) and 17% vs. 9% for CRT devices (CRT-D or CRT-P), respectively, P < 0.001], independently of other factors. A large number of clinical factors were predictive for device usage. Among other, LVEF < 40% and male sex were independent positive predictors for ICD/CRT-D use [odds ratio (OR) = 3.33, P < 0.001; OR = 1.87, P = 0.019, respectively]. Older age was independently associated with less ICD/CRT-D (OR = 0.96 per year, P < 0.001) and more CRT-P/PM use (OR = 1.03 per year, P = 0.006).Conclusions In this large Dutch HF registry, less than half of the patients with reduced LVEF received an ICD or CRT, even if LVEF was <= 30%, and a large variation between centres existed. Patients from implantation centres had more often ICD or CRT. More uniformity regarding guideline-based use of device therapy in clinical practice is needed.
KW - cardiac resynchronization therapy
KW - electrical device therapy
KW - follow-up
KW - guidelines
KW - heart failure
KW - hf
KW - implantable cardioverter defibrillator
KW - implantable cardioverter-defibrillator
KW - primary prevention
KW - real-world heart failure management
KW - reduced ejection fraction
KW - sex-differences
KW - survival
KW - task-force
KW - therapy
KW - SURVIVAL
KW - Electrical device therapy
KW - Real-world heart failure management
KW - GUIDELINES
KW - FOLLOW-UP
KW - Cardiac resynchronization therapy
KW - REDUCED EJECTION FRACTION
KW - THERAPY
KW - Heart failure
KW - Implantable cardioverter defibrillator
KW - IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR
KW - TASK-FORCE
KW - SEX-DIFFERENCES
KW - PRIMARY PREVENTION
KW - HF
U2 - 10.1002/ehf2.12740
DO - 10.1002/ehf2.12740
M3 - Article
C2 - 32395914
SN - 2055-5822
VL - 7
SP - 1771
EP - 1780
JO - Esc heart failure
JF - Esc heart failure
IS - 4
ER -